EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy

Yanying He, Yoon Yeo

WIREs Nanomedicine and Nanobiotechnology · 2026-03 · 18 (2)

DOI: 10.1002/wnan.70052 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 09.03.2026. Verfasst von Yanying He und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Industrial and Molecular Pharmaceutics, Purdue University, West Lafayette, Indiana, USA. Hauptthemen laut MEDLINE: Myeloid-Derived Suppressor Cells, Immunotherapy, Imidazoles, Neoplasms. Die Arbeit nennt 228 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past decade, immunotherapy has emerged as the fourth pillar of cancer therapy, following surgery, chemotherapy, and radiotherapy. However, tumors often evade immune responses by altering the tumor microenvironment (TME), which recruits immunosuppressive cells such as myeloid‐derived suppressor cells (MDSCs), tumor‐associated macrophages, and regulatory T cells. Among these, MDSCs are considered key contributors to immunotherapy failure and have become major targets in new therapeutic strategies. Growing evidence indicates that controlling MDSCs is critical to the success of cancer immunotherapy, and several drug classes have shown feasibility. In this review, we introduce the significance of MDSCs as a target in cancer immunotherapy and highlight different therapeutic approaches to counteract their immunosuppressive functions. We discuss recent efforts to optimize drug delivery for controlling MDSCs, focusing on resiquimod (R848) as a representative drug candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid-Derived Suppressor CellsImmunotherapyImidazolesNeoplasmsDrug Delivery SystemsHumansAnimalsTumor Microenvironment

Stichwörter der Autor:innen

TLR7 agonistcancer immunotherapydrug deliveryimmunosuppressionmyeloid‐derived immunosuppressor cellsresiquimod

Substanzen

resiquimodImidazoles

Autor:innen und Institutionen

  • Department of Industrial and Molecular Pharmaceutics, Purdue University, West Lafayette, Indiana, USA.
  • Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA.
  • Purdue University Institute for Cancer Research, West Lafayette, Indiana, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

He, Y., & Yeo, Y. (2026). Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy. WIREs Nanomedicine and Nanobiotechnology, 18(2). https://doi.org/10.1002/wnan.70052

Vancouver

He Y, Yeo Y. Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy. WIREs Nanomedicine and Nanobiotechnology. 2026;18(2). doi:10.1002/wnan.70052

BibTeX
@article{He2026,
  author = {He, Yanying and Yeo, Yoon},
  title = {Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy},
  journal = {WIREs Nanomedicine and Nanobiotechnology},
  year = {2026},
  volume = {18},
  number = {2},
  doi = {10.1002/wnan.70052}
}
Kostenlos starten →